瓦达司他在慢性肾脏病相关贫血患者中的红细胞生成效应
四项3期随机开放标签临床试验纳入透析依赖和非透析依赖的慢性肾脏病贫血患者,比较瓦达司他与达依泊汀α。瓦达司他在升高和维持目标血红蛋白浓度方面非劣于达依泊汀α,并升高血清促红细胞生成素、循环红细胞和网织红细胞计数,改善铁可利用性。
要点
- 瓦达司他在升高和维持目标血红蛋白浓度方面非劣于达依泊汀α。
- 瓦达司他升高血清促红细胞生成素、循环红细胞和网织红细胞计数。
- 瓦达司他组平均红细胞体积和平均红细胞血红蛋白增加,红细胞分布宽度降低。
核心结论
- 瓦达司他对慢性肾脏病相关贫血患者的红细胞生成有三方面有益效应:增加内源性促红细胞生成素产生、改善红系细胞铁可利用性、增加循环网织红细胞。
研究设计与样本
- 四项3期随机开放标签临床试验,纳入透析依赖和非透析依赖的慢性肾脏病贫血患者,比较瓦达司他与达依泊汀α。
主要发现
- 瓦达司他组与达依泊汀α组达到的血红蛋白浓度相似。
- 与达依泊汀α组相比,瓦达司他组红细胞平均红细胞体积和平均红细胞血红蛋白增加,红细胞分布宽度降低。
- 瓦达司他组血清转铁蛋白浓度(以总铁结合力衡量)升高,血清铁浓度稳定,转铁蛋白饱和度较达依泊汀α组降低。
- 转铁蛋白饱和度降低与瓦达司他组血清铁调素和铁蛋白下降幅度相对大于达依泊汀α组相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with chronic kidney disease (CKD) develop anemia largely because of inappropriately low erythropoietin (EPO) production and insufficient iron available to erythroid precursors. In four phase 3, randomized, open-label, clinical trials in dialysis-dependent and non-dialysis-dependent patients with CKD and anemia, the hypoxia-inducible factor prolyl hydroxylase inhibitor, vadadustat, was noninferior to the erythropoiesis-stimulating agent, darbepoetin alfa, in increasing and maintaining target hemoglobin concentrations. In these trials, vadadustat increased the concentrations of serum EPO, the numbers of circulating erythrocytes, and the numbers of circulating reticulocytes. Achieved hemoglobin concentrations were similar in patients treated with either vadadustat or darbepoetin alfa, but compared with patients receiving darbepoetin alfa, those receiving vadadustat had erythrocytes with increased mean corpuscular volume and mean corpuscular hemoglobin, while the red cell distribution width was decreased. Increased serum transferrin concentrations, as measured by total iron-binding capacity, combined with stable serum iron concentrations, resulted in decreased transferrin saturation in patients randomized to vadadustat compared with patients randomized to darbepoetin alfa. The decreases in transferrin saturation were associated with relatively greater declines in serum hepcidin and ferritin in patients receiving vadadustat compared with those receiving darbepoetin alfa. These results for serum transferrin saturation, hepcidin, ferritin, and erythrocyte indices were consistent with improved iron availability in the patients receiving vadadustat. Thus, overall, vadadustat had beneficial effects on three aspects of erythropoiesis in patients with anemia associated with CKD: increased endogenous EPO production, improved iron availability to erythroid cells, and increased reticulocytes in the circulation.
引用
- Koury MJ, Agarwal R, Chertow GM, et al. Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease. Am J Hematol. 2022. PMID: 35751858. doi:10.1002/ajh.26644
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。